TERN THERAPEUTICS is developing one-time gene therapy treatments specifically targeting rare diseases, with its lead candidate TTX-381 currently in clinical testing for ocular manifestations of CLN2, a form of Batten disease. The company aims to expedite the delivery of transformative therapies to patients worldwide who lack effective treatment options.
Funding
$15M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many rare diseases lack effective treatments, leaving patients with limited or no options. Developing therapies for these conditions is challenging due to small patient populations and the complexities of genetic disorders.
Solution
Tern Therapeutics is focused on developing one-time gene therapy treatments for rare diseases. Their approach involves using genetic treatments to target the underlying causes of these diseases, with the goal of providing long-lasting therapeutic benefits. Their lead candidate, TTX-381, is currently in clinical testing for ocular manifestations of CLN2, a form of Batten disease.
Target Audience
The primary target audience includes patients with rare genetic diseases, particularly those affected by CLN2 Batten disease, and their families.
Features
- Developing one-time gene therapy treatments.
- Lead candidate TTX-381 is in clinical trials for CLN2-related ocular issues.
- Focus on transformative therapies for rare genetic diseases.